The purpose of the trial is to determine whether Sivelestat can improve clot‑breaking function compared with placebo. Participants will be randomly assigned to receive either the study drug or the placebo for several days while they are in the hospital. Blood samples will be taken before treatment and at several time points during the first week to measure levels of proteins such as plasminogen, which helps dissolve clots. Doctors will also monitor standard health indicators, organ function, and any side effects throughout the hospital stay and during follow‑up visits up to three months after treatment.

After the transplant, the treatment is given over about one year. One group receives a reduced dose of the immune-suppressing medicine, while the other group receives the standard dose. During the study, the health of the transplanted kidney is followed, and the study team looks for signs of rejection, infection, kidney function changes, and other serious problems. A biopsy, which is a small sample taken from the kidney, may be used to check for rejection.

The study also looks for dnDSAs, which are new antibodies made by the body against the transplanted kidney, and eGFR, a blood test that helps show how well the kidney is working. Other terms used in the study include ddcfDNA, a small amount of DNA from the transplanted kidney that can be found in the blood, and dialysis, a treatment that replaces some kidney function if the transplant stops working.

Participants will take part in a study involving four different periods where they will receive different treatments in a specific order. During these periods, the administration of brexanolone is given through intravenous means, which means the medicine is delivered directly into a vein. The lorazepam is taken as an oral tablet. By using a crossover design, each person receives each treatment at different times to allow for a direct comparison of the effects.

The purpose of this study is to investigate how long it takes and how well rapid sequence emergence from general anesthesia works, which means bringing someone quickly out of the sleep-like state caused by anesthesia. The study will measure several things during this process, with the main focus being on how long it takes for spontaneous breathing to return, meaning when the person starts breathing on their own again without help. Other measurements will include the time it takes for the person to open their eyes, when reflexes like swallowing and coughing come back, breathing patterns including oxygen levels and breathing rate, heart rate and blood pressure, brain activity levels, the depth of muscle relaxation, and the total time needed to become fully awake as before the anesthesia was given.

During the study, healthy volunteers will receive general anesthesia using the combination of medications mentioned above. The medications will be given through an injection into a vein. After the anesthesia is established, the reversal medications will be administered to bring the volunteers out of anesthesia in a controlled manner. Throughout this process, various measurements will be taken to track how quickly and smoothly the volunteers wake up from the anesthesia and return to their normal state.

The study involves healthy participants who will receive the radioactive tracer during the research. After the tracer is given, special imaging scans called positron emission tomography or PET scans will be performed to track where the tracer travels in the body and how it binds to the CCR9 protein in different areas, particularly in the abdomen. The maximum amount of the tracer that will be given is very small, measured in micrograms, and the treatment period can last up to 60 days.

During the study, participants will undergo PET examinations to measure how much of the tracer is present in different regions of interest in the body. The researchers will calculate values that show how much of the tracer has accumulated in these areas and compare measurements between different PET scans. The study will also monitor any safety concerns or unwanted effects that may occur during the research. This research helps scientists understand how the tracer behaves in the body, which may be useful for future medical applications related to Crohn’s disease.

The purpose of the study is to find out if giving this stem cell treatment through an infusion into the vein can help restore heart function in people who have been recently diagnosed with this type of heart failure. The study will compare how well the heart works in patients who receive the stem cell treatment versus those who receive the placebo. Patients in the study will receive their assigned treatment through infusions and will be followed for twelve months to see how their heart function changes over time.

During the study, doctors will measure various aspects of heart function using different methods. They will check the heart’s pumping ability and the size of the heart chambers at different time points after the treatment. Doctors will also assess how patients feel and function in their daily lives by checking their symptoms, their ability to walk for six minutes, and asking them to complete questionnaires about their quality of life. Blood tests will be performed to measure a substance that indicates heart stress. The study will also carefully monitor any unwanted effects or reactions that patients may experience to ensure the treatment is safe.

The purpose of this study is to examine how memory-related brain networks are preserved or damaged in different groups of patients with memory disorders from various causes, and to understand the different types of memory strategies that memory experts use. The study will also include healthy people, professional theater actors, and memory athletes who compete in memory competitions. By comparing these different groups, researchers want to learn more about how the brain supports memory and what happens when memory becomes impaired.

Participants will undergo several days of testing and examinations. These will include brain scans using different techniques, memory and thinking tests, questionnaires about daily life and sleep, sleep monitoring, blood tests, and physical measurements. Some participants will receive the imaging substances to allow detailed pictures of their brain to be taken. The study will measure the size of different brain areas, how blood flows through the brain, and the presence of certain proteins that are associated with memory disorders. The information gathered will help researchers understand the brain structures and networks that support memory function in both healthy individuals and those with various memory problems.

Patients participating in this study will have experienced persistent headaches for at least 24 hours despite receiving conservative treatment such as rest, fluids, and pain medication. They will receive either the sphenopalatine block or the blood patch procedure. After the treatment, headache intensity will be measured using a scale from zero to ten, where zero means no pain and ten represents the worst possible pain. These measurements will be taken at multiple time points: at the start of the procedure, then at 30 minutes, one hour, two hours, six hours, 24 hours, 48 hours, and seven days after treatment. The treatment period lasts one day, with follow-up assessments continuing for seven days.

The study will also track several other aspects of patient care and recovery. This includes monitoring how much pain medication patients need after the procedure, whether additional treatment with a blood patch becomes necessary, and how long patients need to stay in the hospital during the seven-day period following treatment. Any unwanted effects that occur during the procedure will be recorded, as well as any serious complications. Patient satisfaction with the treatment will be assessed seven days after the procedure using a rating scale. The study aims to determine whether the sphenopalatine block offers a comparable alternative to the blood patch for managing this painful condition.

The study involves several chemotherapy medications that are commonly used to treat pancreatic cancer. These include capecitabine, paclitaxel, irinotecan, gemcitabine, fluorouracil, oxaliplatin, and calcium folinate. Some medications are given by mouth, while others are administered through an intravenous line. The treatment period typically lasts for 6 months.

The research is divided into two parts. The first part checks if it’s possible to grow these mini-tumors and test different chemotherapy combinations on them within 12 weeks after surgery. The second part examines how well patients do when their treatment is chosen based on how their laboratory-grown tumor responds to different chemotherapy combinations. The effectiveness of the treatment will be measured by tracking how long patients remain free of cancer after treatment.

The purpose of the study is to compare the outcomes of radiation treatment when planned using PSMA PET imaging versus standard imaging methods. The study involves two groups of patients – one group will receive radiation therapy planned using conventional imaging, while the other group will have their treatment planned using PSMA PET scans. Each participant will receive a single dose of the imaging agent before their radiation treatment planning.

During the study, patients will be monitored for several years to track their response to treatment and any changes in their cancer status. The monitoring includes regular check-ups and various tests to assess how well the treatment is working. The study medication (Locametz) is already approved for use in medical imaging and will be given as a single dose of up to 259 MBq (a measure of radioactivity).

The purpose of the study is to determine whether using this special contrast-enhanced imaging technique can provide better information about cancer spread to lymph nodes compared to standard imaging methods. This is important both before and after patients receive initial cancer treatment with chemotherapy and radiation therapy.

During the study, participants will receive a single dose of Ferrotran through an infusion into their vein. The amount given depends on the person’s weight. They will then undergo MRI scanning to create detailed images of the lymph nodes. The imaging procedure will be performed twice – once before starting cancer treatment and once after completing it. The total duration of participation in the imaging part of the study is 2 days.

The purpose of this research is to show that mannitol is not inferior to Plenvu® when used as a same-day bowel preparation regimen before colonoscopy. Participants will be randomly assigned to use either mannitol or Plenvu® to clean their bowels before their scheduled colonoscopy. The endoscopist (the doctor performing the colonoscopy) will not know which preparation each patient received, allowing for an unbiased assessment of how clean the bowel is during the procedure.

During the study, patients will take their assigned bowel preparation according to instructions, undergo their scheduled colonoscopy, and answer questions about their experience with the preparation, including ease of use, taste, and willingness to use it again. The study will also monitor for any side effects from either preparation and collect information about how well each preparation cleaned the bowel and allowed for detection of any abnormalities.

The purpose of the study is to use this new MRI technique to identify and describe metabolic changes in patients with ALS and TIA. Participants in the study will receive an injection of Hyperpolarized [1-13C]pyruvate, which will help highlight certain metabolic processes in the brain during the MRI scan. This approach aims to provide a clearer picture of how these diseases affect brain function.

Throughout the study, participants will undergo MRI scans after receiving the injection. The study will monitor how the injected substance interacts with the brain’s metabolism, focusing on how it converts to other substances like bicarbonate, lactate, and alanine. This information will be gathered alongside clinical examinations and patient interviews to better understand the impact of ALS and TIA on brain health.

The purpose of the study is to explore the relationship between brain inflammation and genetic factors in people with schizophrenia. The study will include both patients with schizophrenia and healthy volunteers. Participants will undergo PET scans to measure brain inflammation and may also have other types of scans, like MRI, to look at brain structure and connections. The study will also check for other health markers, such as cholesterol levels and blood sugar, to see how they relate to brain inflammation.

The study will take place over several years, with the goal of better understanding how genetic factors might influence brain inflammation in schizophrenia. This research could help in developing new ways to diagnose or treat the condition in the future.

The purpose of the study is to understand how the immune system, particularly the lymph nodes, responds to these vaccines. Lymph nodes are small glands that play a crucial role in the body’s defense against infections. The study will look at the timing of the peak response of certain immune cells, known as B cells, in the lymph nodes after vaccination. It will also examine other immune cells, such as T cells, and various markers that indicate how the immune system is reacting.

Participants in the study will receive one of the vaccines and will have samples taken from their lymph nodes and blood at different times. These samples will help researchers understand the changes in immune cells and the levels of cytokines, which are substances that help regulate the immune response. The study aims to provide insights into how well the vaccines work in stimulating the immune system to protect against pneumococcal disease.

The purpose of the study is to determine how effective the intertransverse process block is in managing pain. Participants in the study will receive either a single or multiple injections of the medications. The study will observe how well the block works by measuring the number of areas on the body that become numb, as well as other factors like changes in skin temperature and blood pressure. Participants will also be asked about their satisfaction with the pain relief they experience.

The study is designed to be a crossover trial, which means that participants will receive both types of injections at different times. This allows researchers to compare the effects of single versus multiple injections in the same individuals. The trial is conducted with healthy volunteers to ensure the safety and effectiveness of the procedure before it is used more widely in patients undergoing breast cancer surgery.

Participants in the study will receive a special injection called Fludeoxyglucose (18F)-Curium, which is a solution used to help visualize certain processes in the body. This solution is given through an intravenous infusion, meaning it is delivered directly into the bloodstream. The purpose of the study is to collect data on how often these immune-related side effects occur, how they affect patients with and without existing joint or muscle conditions, and how patients respond to treatment.

The study will follow participants over time to observe the development of these side effects and gather information on their health and treatment responses. This information will help doctors better understand and manage these side effects in the future, improving care for patients undergoing cancer treatment with immune checkpoint inhibitors.

The purpose of the study is to explore the metabolic changes in the brain’s dopamine network in patients who have experienced a traumatic coma. Participants will receive the [18F]LBT-999 injection, and then undergo a PET scan to observe how the agent binds to dopamine transporters in the brain. This will help researchers compare the brain activity of patients with traumatic coma to those without such injuries. The study will also look at how these changes relate to the patient’s recovery and overall brain function over time.

Throughout the study, participants will be monitored at different intervals, including 3 months, 6 months, and 1 year after the initial brain injury. This will help assess their neurological recovery and quality of life. The study aims to provide valuable insights into the recovery process of patients with severe traumatic brain injuries and potentially improve future treatment approaches.

Participants in the study will undergo the Hyperpolarized [1-13C]pyruvate MRI scan. This involves receiving an injection of the contrast agent through a vein, a process known as intravenous administration. The study will compare the results of these scans to standard imaging methods like MRI and CT scans, which are commonly used to diagnose liver cancer. The goal is to see if the new method can provide more detailed information about the metabolism and blood flow in liver tumors.

The study is designed to last until 2026, with participants being monitored over time to assess the effectiveness of the Hyperpolarized [1-13C]pyruvate MRI in detecting liver cancer early. This research could potentially lead to better ways of diagnosing liver cancer, especially in its early stages, which is crucial for effective treatment. The study does not involve any other diseases or medications, and participants may receive a placebo as part of the trial process.

The purpose of this study is to understand how the body processes and responds to amiodarone when given in these two different ways. This involves measuring the levels of amiodarone and its active component, N-desethylamiodarone, in the blood, as well as in samples from the lungs and breath. The study will involve patients who are in the intensive care unit and are receiving mechanical ventilation, which is a machine that helps them breathe.

Participants in the study will receive either the standard intravenous form of amiodarone or the enteral form as part of their treatment for atrial fibrillation. The study will last for a maximum of seven days, during which the effects of the medication will be closely monitored. This research aims to provide valuable insights into the best way to administer amiodarone to critically ill patients with atrial fibrillation, potentially improving treatment outcomes for this condition.

The purpose of the study is to determine how accurately the Gallium-68-Tilmanocept PET/CT can detect these lymph nodes compared to the traditional method using Technetium (99mTc). Participants in the study will undergo imaging with both methods before their surgery. This will help doctors understand which method is better at finding the lymph nodes that need to be examined for cancer spread.

During the study, participants will receive a small amount of the imaging substances near the tumor area. This is done to highlight the lymph nodes during the imaging process. The study aims to improve the way doctors detect and treat oral cancer by finding the most effective method for identifying affected lymph nodes. The trial will help gather important information that could lead to better outcomes for patients with this type of cancer.

The purpose of the study is to explore and compare how effectively these two imaging methods can find tumors. Patients will receive both types of scans, and the results will be compared to see which method is better at detecting the cancer. The study will also look at how the cancer appears in these scans compared to a standard imaging method called computed tomography (CT), which uses X-rays to create detailed pictures of the inside of the body.

During the study, patients will undergo these imaging tests, and the results will be analyzed to determine the best way to detect tumors in this type of kidney cancer. The study will help doctors understand which imaging method provides the most accurate information about the presence and spread of the cancer, potentially leading to better diagnosis and treatment options for patients with metastatic renal cell carcinoma.

The purpose of the study is to evaluate how these treatments affect lung function using a special imaging technique called PET/CT, which combines positron emission tomography and computed tomography to create detailed images of the lungs. Participants will receive either the treatment or a placebo and will undergo several imaging sessions to monitor changes in lung function over time. The study aims to understand how well the lungs are working after treatment and to identify any improvements in breathing and overall lung health.

Throughout the study, participants will have regular check-ups and imaging tests to track their progress. The study will last for a period of time, during which participants will be closely monitored by healthcare professionals. The goal is to gather information that could help improve treatment options for people with pulmonary embolism in the future.

The purpose of the study is to see how well the PET scan can predict the development of rheumatoid arthritis in people with ACPA positive arthralgia. Participants will receive the PET scan and be monitored over a period of one year to see if they develop clinical arthritis, which means arthritis that can be diagnosed by a doctor. The study aims to determine how accurately the PET scan can identify those who are likely to develop arthritis.

During the study, participants will undergo a PET scan using the [18F]Fluor-PEG-Folate solution, which is administered through an injection into a vein. The study will track the participants’ health over the course of a year to observe any changes in their condition. The results will help researchers understand the relationship between PET scan results and the likelihood of developing rheumatoid arthritis, potentially leading to earlier and more accurate identification of individuals at risk.

The purpose of the study is to see how well the [68Ga]Ga-PentixaFor PET/CT method works compared to the AVS method in identifying and understanding the condition. Participants in the study will be randomly assigned to either the PET/CT imaging or the AVS procedure. The study will follow participants for a period of time to observe the outcomes of each method, particularly focusing on how they affect blood pressure and overall health.

Throughout the study, researchers will also look at various factors such as the quality of the images produced by the PET/CT scans, the safety of the procedures, and the overall experience of the participants. The study aims to provide valuable information that could improve the diagnosis and treatment of Primary Aldosteronism in the future.

The purpose of the study is to determine how accurate the 68 Gallium citrate PET/CT scan is in diagnosing chronic infections in artificial hip or knee joints. Participants in the study will undergo this imaging procedure to see if it can reliably identify infections. The study will also compare the results of the 68 Gallium citrate PET/CT scan with another imaging method called marked polynuclear scintigraphy to evaluate which method is more effective.

Throughout the study, researchers will assess the accuracy of the 68 Gallium citrate PET/CT scan by looking at its ability to correctly identify infections. They will also examine how consistent the results are when interpreted by different observers. The study aims to provide valuable information that could improve the diagnosis of infections in people with artificial joints, potentially leading to better treatment outcomes.

The purpose of this study is to determine whether it is possible to perform both imaging methods at the same time to better understand how tumors use energy. During the study, participants will receive two different injectable substances: hyperpolarized [1-13C]pyruvate and Fluor-18-FDG. Both substances will be given through an intravenous injection, and then special images will be taken using a combined PET/MR scanner.

This research will help doctors better understand how tumors process different nutrients and may lead to improved ways of detecting and monitoring cancer. The imaging procedure will be performed once for each participant, and the total dose of each substance has been carefully calculated to ensure safety.

The purpose of the study is to optimize a scanning technique known as MR-hyperpolarisation in patients with pancreatic cancer. This technique uses the hyperpolarized pyruvate to enhance the quality of images obtained from the pancreas and other related areas, such as the liver. The study aims to gather baseline data on how this technique works in different parts of the body, including both cancerous and non-cancerous tissues. Additionally, the study will confirm the safety and feasibility of using hyperpolarized pyruvate in these patients.

Participants in the study will receive the hyperpolarized pyruvate injection, and then undergo MR-hyperpolarisation scanning. The study will explore how the signals from this scanning technique relate to the patients’ response to chemotherapy, which will be further tested in future studies. The trial will help researchers understand the potential of this imaging method in improving the diagnosis and treatment of pancreatic cancer.

The study will compare two different approaches during dialysis sessions: one using Medialipide, which is a special fat-based solution containing medium-chain triglycerides and soya oil, and another using standard sodium chloride solution (salt water). Each dialysis session in the study will last for 4 hours, during which these solutions will be given through an intravenous line.

During the treatment, researchers will measure how effectively the dialysis removes various harmful substances from the blood. They will also monitor the safety of using Medialipide by checking for side effects such as nausea, vomiting, headaches, and by measuring blood levels of fats and liver function. Blood samples will be taken at different times during the dialysis session to measure the levels of various substances.

The purpose of the study is to observe and describe how the tracer behaves in the body and how it highlights different areas affected by the diseases. The study will involve a single injection of the tracer, followed by a PET/CT scan to capture images of the affected areas. This will help researchers understand the intensity and location of the disease activity in the body.

The study will take place over a period of time, with participants undergoing the imaging process at the start of the study. The information gathered from these images will be used to better understand the diseases and potentially improve future treatments. The study aims to provide valuable insights into how these diseases affect the body and how they can be better managed in the future.

During the trial, participants will receive an injection of a substance called 18F-PSMA-1007, which helps highlight cancer cells during the PSMA-PET scan. Additionally, other substances like Buscopan, Dotarem, and Glucagon may be used to assist in the imaging process. These substances are administered through injections and are commonly used in medical imaging to improve the quality of the scans.

The study will monitor participants for a short period after the imaging procedures to ensure their safety and to record any side effects. The trial aims to improve the understanding of how these imaging techniques can be used to better plan treatments for prostate cancer, potentially leading to more effective management of the disease. Participants will not be given a placebo during this study.

Participants in the study will receive tacrolimus orally, which means they will take it by mouth. The study will last for a period of 14 days. During this time, researchers will monitor changes in the participants’ glycemic profile, which refers to the levels of sugar in the blood. The goal is to determine if there is a significant change in blood sugar levels from the start of the treatment to the end of the 14-day period.

This study is important for understanding how tacrolimus might affect blood sugar levels in patients who are on dialysis and preparing for a kidney transplant. The findings could help improve the management of these patients’ conditions and provide insights into the safe use of tacrolimus in this specific group of patients.

The purpose of the study is to determine how effective the 68Ga-PET/CT scan is in diagnosing infections in patients who have artificial heart valves and are suspected of having this type of infection. The study will compare the results of the 68Ga-PET/CT scan with another imaging method called 18FDG-PET/CT to see which one provides better information about the infection.

Participants in the study will undergo the 68Ga-PET/CT scan, and the results will be analyzed to see how well this method can identify the infection. The study will also look at how consistent the results are when different doctors review the scans. This research aims to improve the diagnosis and treatment of infections in patients with artificial heart valves.

The purpose of the study is to develop a model that can identify ovarian cancer more accurately and determine the severity of the disease. This involves analyzing blood samples and using functional and metabolic MRI techniques. The study aims to improve the accuracy of diagnosing ovarian cancer and to help doctors decide on the best treatment approach. Participants will undergo MRI scans and provide blood samples, which will be analyzed to see if these methods can distinguish between patients with and without cancer.

The study will also assess whether the use of Hyperpolarized [1-13C]pyruvate in MRI contributes to a more accurate diagnosis and staging of ovarian cancer. Additionally, the study will evaluate the repeatability and reliability of these imaging techniques in patients suspected of having ovarian cancer. The ultimate goal is to enhance the tools available for diagnosing and planning the treatment of ovarian cancer, potentially leading to better outcomes for patients.

The purpose of the study is to improve the way doctors assess the activity of the disease and predict how well patients will respond to treatment. Participants in the study will receive the treatment and undergo imaging tests to see how the disease is progressing. The study will compare the results of these imaging tests with other standard methods to determine if the new approach provides better information about the disease.

Throughout the study, participants will be monitored for changes in their condition over a period of several weeks. The study aims to see if the new imaging method can help doctors make better treatment decisions and improve outcomes for patients with axial spondyloarthritis. The trial will also look at how the treatment affects patients’ quality of life and overall health.

The purpose of the study is to find out if using genetic information can help doctors choose the best pain treatment for each patient, making it more effective and reducing side effects. Participants in the study will be randomly assigned to receive either the standard pain treatment or a treatment plan based on their genetic test results. This will help researchers understand if the genetic test can improve pain management.

During the study, participants will take the medications orally, which means they will swallow them as pills or capsules. The study will last for a short period, up to three days, which is typical for managing pain after surgery. By comparing the outcomes of the different treatment plans, the study aims to provide insights into whether genetic testing can be a useful tool in personalizing pain management for better results.

In addition to the Xenon (129Xe) gas, the study will also use a contrast agent called Gadovist, which is injected into the body to help highlight certain areas during imaging. The study aims to understand how these imaging techniques can be used to track the progression of lung disease and the effects on the heart. Researchers will also evaluate how patients respond to treatments that aim to slow down the scarring process.

Participants in the study will undergo imaging sessions where they will inhale the Xenon (129Xe) gas and receive the Gadovist injection. These sessions will help researchers gather information about lung function and heart health. The study will take place over a period of time, allowing researchers to monitor changes and gather valuable data on the effectiveness of these imaging techniques in managing lung diseases.

The purpose of the study is to see how well the 68Ga-satoreotide trizoxetan tracer is taken up by cancer cells in patients with these types of lung cancer. During the study, patients will receive an injection of the tracer, and then undergo a PET/CT scan. This scan combines the PET scan with a computed tomography or CT scan, providing detailed images of the cancer. The study will compare these images to previous scans to see if the new tracer can identify cancerous areas more effectively.

The study will also measure certain parameters in the cancerous areas, such as how much of the tracer is absorbed, and compare these measurements to those in normal organs like the lung, kidney, and liver. This will help researchers understand how well the tracer can distinguish between cancerous and non-cancerous tissues. The study is expected to continue until mid-2026.

The purpose of the study is to see how well the 68Ga-FAPi-46 PET-CT scan can show and measure the activity of fibroblasts, which are cells involved in the healing process, during the early stages of healing in perianal Crohn’s fistulas. Participants in the study will undergo imaging at the start and at different times during the study to track changes. The study will help researchers understand how the healing process can be monitored using this imaging technique.

Throughout the study, the researchers will collect visual and quantitative data from the imaging to assess how the fistulas are healing over time. This information will be compared with other clinical assessments to provide a comprehensive view of the healing process. The study aims to improve understanding of how to monitor and potentially enhance the treatment of perianal Crohn’s fistulas using advanced imaging methods.

Participants in the study will receive an injection of the [18F]PSMA-11 solution, which is administered through a vein. After the injection, a PET scan will be performed to capture images of the cancerous areas. The study aims to observe how much of the imaging agent is taken up by the cancerous lesions, which can help in understanding the extent of the disease. This process will be repeated as needed to gather enough information for the study.

The study will last for a period during which all necessary scans and evaluations will be completed. The results will help determine the effectiveness of [18F]PSMA-11 in providing clear images of cancerous lesions in patients with advanced head and neck squamous cell carcinoma and thyroid carcinoma. This information could be valuable in improving the diagnosis and treatment planning for these types of cancer in the future.